Axsome Therapeutics AXSM announced top-line data from the phase III PARADIGM study, which evaluated solriamfetol for the ...

Axsome Therapeutics (NASDAQ:AXSM) traded lower in the premarket on Tuesday after the company said solriamfetol, its ...

Axsome Therapeutics (NASDAQ:AXSM – Get Free Report)‘s stock had its “buy” rating reissued by analysts at Needham & Company ...

After Axsome Therapeutics (AXSM) yesterday reported negative results from its Phase 3 major depressive disorder trial evaluating Sunosi as a ...

CNS specialist Axsome Therapeutics has announced results from the PARADIGM Phase III proof-of-concept trial of solriamfetol ...

Axsome's Phase 3 trial for solriamfetol in MDD did not meet its primary endpoint, but positive data in severe EDS patients ...

In trading on Tuesday, shares of Axsome Therapeutics Inc (Symbol: AXSM) entered into oversold territory, hitting an RSI reading of 29.9, after changing hands as low as $107 per share. By ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Axsome Therapeutics (AXSM) stock gains as solriamfetol, its experimental drug for ADHD succeeds in a Phase 3 trial. Read more ...

Mizuho Securities analyst Graig Suvannavejh maintained a Buy rating on Axsome Therapeutics (AXSM – Research Report) today and set a price ...

It has been about a month since the last earnings report for Axsome Therapeutics (AXSM). Shares have lost about 0.8% in that time frame, outperforming the S&P 500. Will the recent negative trend ...

KLP Kapitalforvaltning AS acquired a new stake in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM – Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities ...